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Abstract
To date, more than 200 microRNAs have been described in humans; however, the precise 
functions of these regulatory, non-coding RNAs remains largely obscure. One cluster of 
microRNAs, the mir-17–92 polycistron, is located in a region of DNA that is amplified in human 
B-cell lymphomas1. Here we compared B-cell lymphoma samples and cell lines to normal tissues, 
and found that the levels of the primary or mature microRNAs derived from the mir-17–92 locus 
are often substantially increased in these cancers. Enforced expression of the mir-17–92 cluster 
acted with c-myc expression to accelerate tumour development in a mouse B-cell lymphoma 
model. Tumours derived from haematopoietic stem cells expressing a subset of the mir-17–92 
cluster and c-myc could be distinguished by an absence of apoptosis that was otherwise prevalent 
in c-myc-induced lymphomas. Together, these studies indicate that non-coding RNAs, specifically 
microRNAs, can modulate tumour formation, and implicate the mir-17–92 cluster as a potential 
human oncogene.
MicroRNAs (miRNAs) have emerged relatively recently as a new class of small, non-coding 
RNAs that regulate gene expression. Nascent primary miRNA transcripts (pri-miRNAs) are 
processed sequentially by two RNase III enzymes, Drosha and Dicer2,3, to yield mature 
miRNAs, ranging from 18 to 24 nucleotides (nt) in length. miRNAs are incorporated into 
the RNA interference (RNAi) effector complex, RISC, and target specific messenger RNAs 
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for translational repression or mRNA cleavage4–6. Although hundreds of miRNAs have 
been cloned and/or predicted, only a handful have been functionally characterized. For 
example, lin-4 and let-7 regulate the timing of larval development in C. elegans7,8. Left/
right asymmetric gene expression in C. elegans chemosensory neurons is controlled by lsy-6 
and miR-273 (refs 9, 10). Bantam stimulates cell growth and prevents apoptosis in 
Drosophila11, and miR-181 potentiates B-cell differentiation in mammals12. These findings, 
in combination with computational target predictions, are consistent with miRNAs 
regulating a broad spectrum of physiological and developmental processes.
Microarray-based expression studies have indicated specific alterations in human miRNA 
expression profiles that correlate with particular tumour phenotypes (J.M.T. and S.M.H., 
unpublished data). Among those that show altered expression, the mir-17–92 cistron is 
located at 13q31, a genomic locus that is amplified in cases of diffuse large B-cell 
lymphoma, follicular lymphoma, mantle cell lymphoma, primary cutaneous B-cell 
lymphoma and several other tumour types1,13. There are only two annotated genes in the 
epicentre of this amplicon, c13orf25 and GPC5. Previous studies have shown that c13orf25 
is the only one of the two genes for which increased expression correlates with the presence 
of the amplicon1. Therefore, c13orf25 had been implicated as a target of the 13q31 
amplicon1. It is unlikely that c13orf25 actually encodes a protein, as predicted open reading 
frames (ORFs) encode only short peptides (<70 amino acids), which are not conserved in 
closely related species. Instead, the c13orf25 transcript appears to be the functional 
precursor of a series of seven microRNAs: miR-17-5p, miR-17-3p, miR-18, miR-19a, 
miR-20, miR-19b-1 and miR-92-1 (Fig. 1a). Additionally, this cluster is related to the 
homologous mir-106a–92 cluster on chromosome X and the mir-106b–25 cluster on 
chromosome 7 (ref. 14; Fig. 1a). Alignment of the human c13orf25 locus and its murine 
orthologue revealed extensive sequence conservation only within the mir-17–92 polycistron 
and its immediate flanking sequence. Several of the expressed-sequence-tags (ESTs) derived 
from c13orf25 and its mouse orthologue terminate at the 3′ end of mir-17–92 cluster, 
consistent with the presence of a Drosha processing site at this location (Fig. 1b).
A principal consequence of 13q31-q32 amplification could be an increase in the abundance 
of mature miRNA species from the mir-17–92 cluster. We acquired four cell lines 
previously described as carrying amplifications in the 13q31-q32 region1 and confirmed the 
gene dosage increase at the c13orf25 locus in three of those cell lines using quantitative 
polymerase chain reaction (PCR) analysis. The abundance of 191 mature miRNAs was 
assessed in these four cell lines and compared to normal B-cells, and to five leukaemia and 
lymphoma cell lines lacking the amplicon (Fig. 1c and Supplementary Fig. 1). Using a 
significance analysis of microarrays (SAM) analysis15, we identified six miRNAs for which 
high-level expression correlated with increased gene dosage of c13orf25 (see Supplementary 
Table 1). Five were from the mir-17–92 cistron, and the sixth, miR-106a, was identified as a 
probable result of cross-hybridization to miR-17-5p, from which it differs at only two 
terminal nucleotides (Fig. 1c). This hypothesis is supported by the observation that the 
mir-106a–92 locus does not show copy number alterations in these cell lines (not shown). In 
each cell line, expression levels correlated with the copy number of the mir-17–92 locus 
(Fig. 1c, lower panel).
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We also examined the expression of pri-mir-17–92 in a series of human tumour samples 
comprising both lymphomas and colorectal carcinomas. Of 46 lymphoma samples, 
including 13 diffuse large B-cell lymphomas and 6 follicular lymphomas, we saw significant 
(greater than fivefold) overexpression of pri-mir-17–92 in 65% of the samples. Considering 
all of the B-cell lymphoma samples analysed, the average increase in pri-miRNA expression 
was about tenfold (Fig. 1d). In contrast, colorectal carcinomas rarely showed over-
expression of the pri-miRNA. Increases in expression from this locus were less common 
(15% of samples showed greater than fivefold upregulation), and the degree of 
overexpression was substantially lower (Fig. 1d).
Considered together, our data prompted the hypothesis that mir-17–92 might contribute to 
tumour development. To test this idea directly, we used a mouse model of human B-cell 
lymphoma. Transgenic animals carrying a c-myc oncogene, driven by the immunoglobulin 
heavy-chain enhancer (Eμ), develop B-cell lymphomas by 4–6 months of age16. Similarly, 
haematopoietic stem cells (HSCs) derived from fetal livers of Eμ-myc transgenic mice 
generate B-cell lymphomas with comparable latency when transplanted into lethally 
irradiated recipients17–20 (Fig. 2a). We therefore infected Eμ-myc/+ HSCs with a murine 
stem cell virus (MSCV) retrovirus that directs expression of a truncated cluster comprising 
mir-17–19b-1 (hereafter mir-17–19b), the vertebrate-specific portion of the mir-17–92 
miRNA cistron (Fig. 1a). This virus also contained a green fluorescent protein (GFP) 
transgene, allowing us to follow infected stem cells in vitro and in vivo (Fig. 2a). Mice 
reconstituted with Eμ-myc/+ HSCs carrying a control MSCV vector developed lymphomas 
after the expected latency (3–6 months), with incomplete penetrance (Fig. 2b). Similarly, we 
examined >40 animals reconstituted with Eμ-myc/+ HSCs expressing subsets of 96 different, 
single microRNAs (see Supplementary Table 2). Although we did not confirm miRNA 
overexpression for every case, we did not observe any significantly accelerated onset of 
disease. In contrast, 100% of the animals co-expressing the mir-17–19b polycistron and c-
myc developed leukaemias at an average of 51 days following transplantation (s.d. ±13 days, 
P < 0.0001 compared with MSCV controls using the log rank test), and died of B-cell 
lymphomas at an average age of 65 days (s.d. ±13 days, P < 0.0001 compared to MSCV 
controls; Fig. 2b). In all but one case, primary lymphomas could be visualized by virtue of 
the linked GFP marker (Fig. 2c and Table 1). The mature miRNAs from the mir-17–19b 
cluster show high-level expression in these tumours, compared with miRNAs from the 
paralogous mir-106a–92 locus, and also have similar mir-17–19b expression levels 
compared to the Karpas 1718 lymphoma cell line, which has increased c13orf25 gene 
dosage (see Supplementary Fig. 2).
The full mir-17–92 cistron was also tested in a small cohort of animals. Although similar 
results were obtained compared to those animals reconstituted with HSCs expressing 
mir-17–19b, studies in cell lines indicated that the construct used to express the entire cluster 
gave lower levels of mature miRNAs. We therefore focused most of our study on the 
truncated mir-17–19b cluster. In these ongoing studies, we have yet to find any individual 
miRNA from the mir-17–19b cluster that can accelerate tumour formation to the extent seen 
with the intact polycistron (not shown).
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The Eμ-myc/mir-17–19b lymphomas are true malignancies rather than hyperplasias, because 
primary tumour cells, when transplanted into C57B6/J recipients, induce B-cell lymphomas 
in 2–3 weeks that result in lethality after 4–5 weeks (data not shown). The secondary 
tumours show pathological features indistinguishable from the original tumours, and retain 
tumorigenic potential after two additional rounds of serial transplantation (data not shown). 
Therefore, a microRNA cluster can accelerate Eμ-myc induced tumorigenesis in mice.
The pathological hallmarks of Eμ-myc/mir-17–19b mosaic animals included massive 
enlargement of lymph nodes, splenic hyperplasia, infiltration of the thymus by lymphoma 
cells, and leukaemia (Fig. 2c). Animals with advanced lymphomas showed extramedullary 
haematopoiesis due to functional failure of the bone marrow. Furthermore, 6 out of 14 
animals showed hind limb paralysis, associated with substantial tumour growth at the 
lumbar node. Tumours resulting from combined c-myc and mir-17–19b expression 
consistently invaded visceral organs outside the lymphoid compartment, including liver, 
lung and occasionally kidney (Figs 2c, 3b and Table 1). Additionally, Eμ-myc/mir-17–19b 
lymphomas show a high mitotic index without extensive apoptosis (Fig. 3a). This contrasts 
with the Eμ-myc/MSCV tumours lacking the microRNA cluster, which show a high degree 
of apoptosis (Fig. 3a). These findings indicate that cooperation between Eμ-myc and mir-17–
19b gives rise to highly malignant, disseminated lymphomas capable of evading normal 
apoptotic responses to inappropriate proliferation.
Eμ-myc-induced lymphomas originate from the B-lymphoid lineage. However, the 
developmental characteristics of these tumour cells are not stage-specific, as they can 
resemble either mature B cells or pre-B cells. To examine the cell lineage of the Eμ-myc/
mir-17–19b lymphomas, we assessed the expression of cell-surface markers, including the 
B-cell-specific marker B220 and the T-cell-specific markers CD4 and CD8a. All tumours 
were found to be of B-cell origin, staining positive for B220 and negative for both CD4 and 
CD8a (Fig. 3c and Table 1). We next analysed these tumours for CD19 and IgM expression 
to distinguish pre-B from mature B cells. With one exception, Eμ-myc/mir-17–19b 
lymphomas were derived purely from the pre-B cell lineage (low to absent Thy1.2 staining, 
CD19+B220+IgM−) (Table 1), suggesting that overexpression of mir-17–19b strongly 
favours transformation of B-cell progenitors under our experimental conditions.
Exactly how overproduction of mir-17–19b might promote oncogenesis is unclear. At a 
minimum, studies of tumour pathology suggest that increased expression of this cluster 
mitigates the pro-apoptotic response to elevated myc expression in vivo. Furthermore, we 
have previously shown that this miRNA cistron is highly expressed in embryonic stem cells, 
with expression levels decreasing during embryonic development in mice21. It is therefore 
tempting to speculate that these miRNAs promote ‘stem cell’ properties or specify 
characteristics of early developmental lineages. A detailed, mechanistic understanding of 
how this non-coding RNA cluster acts as an oncogene is at present hampered by the lack of 
a validated biochemical strategy for identifying miRNA targets.
Previous circumstantial evidence has indicated the potential involvement of a number of 
miRNAs in tumorigenesis. Although miRNAs only represent 1% of the mammalian 
genome, more than 50% of miRNA genes are located within regions associated with 
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amplification, deletion and translocation in cancer22. Expression studies of various tumour 
types have also revealed specific alterations in miRNA profiles22–25. For example, mir-15 
and mir-16 are frequently deleted and/or downregulated in B-cell chronic lymphocytic 
leukaemia26, miR-143 and miR-145 show decreased abundance in colorectal neoplasia25, 
and miR-155 and its non-coding RNA host gene, BIC, are upregulated 100-fold in Burkitt’s 
lymphoma patients24. Here, we have shown that one miRNA polycistron is not only the 
subject of tumour-specific amplification, but that it is also overexpressed in tumours and 
tumour cell lines, and can act as an oncogene in vivo. Our results indicate that non-coding 
RNAs might act as integral parts of the molecular architecture of oncogene and tumour 




Five micrograms of total RNA was labelled with RNA ligase and a Cy3-conjugated 
dinucleotide, and hybridized to custom oligonucleotide microarrays as described in ref. 21. 
Cy3 median intensity values were filtered to remove data points that did not exceed 
background levels by twofold. Values were log2-transformed and median-centred by array. 
Clustering was performed with Cluster (Stanford University), using values that were 
median-centred by gene. Dendrograms and expression maps were generated using Treeview 
(Stanford).
Cell lines
The measurement of miRNA abundance was carried out using the following human cell 
lines: Karpas 1718 (derived from splenic lymphoma with villous lymphocytes, provided by 
A. Karpas), OCI-Ly4, OCI-Ly7 and OCI-Ly8 (derived from diffuse large B-cell lymphoma, 
provided by R. Dalla-Favera). The cell lines lacking the 13q31-q32 amplicon were Raji (B-
cell, derived from Burkitt’s lymphoma, ATCC); Namalwa (B-cell, derived from Burkitt’s 
lymphoma, ATCC); HG 1125 (EBV-transformed human lymphoblastoid, provided by B. 
Stillman); Manca (lymphoblast-like, derived from chronic myelogenous leukaemia); Jurkat; 
proliferating B-cells (spleenic B-cells isolated from a C57B6/Ly5.2 mouse and stimulated to 
proliferate in culture with lipopolysaccharide, provided by I. Weissman); and normal B cells 
(derived from cord blood, Cambrex).
PCR and copy number analysis
Tumour samples were obtained from the Cooperative Human Tissue Network (http://www-
chtn.ims.nci.nih.gov). Corresponding normal tissue RNA from five individuals was 
purchased from Biochain Institute Inc. For fluorogenic real-time PCR, primers that amplify 
mir-17–92 pri-miRNA and β-actin mRNA (control), and probes were designed using Primer 
Express software (V.2): mir-17–92 forward primer, 3′-
CAGTAAAGGTAAGGAGAGCTCAATCTG-5′; reverse primer, 3′-
CATACAACCACTAAGCTAAAGAATAATCTGA-5′; mir-17–92 probe, (6-FAM)-
TGGAAATAAGATCATCATGCCCACTTGAGAC-(TAMRA); β-actin forward primer, 3′-
GCAAAGACCTGTACGCCAACA-5′; reverse primer, 3′-TGCATCCTGTCGGCAATG-5′; 
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β-actin probe, (6-FAM)-TGGCGGCACCACCATGTACC-(TAMRA). The ratios of RNA 
species detected by mir-17–92 primers and β-actin primers in each RNA sample were 
determined in triplicate by reverse-transcription, quantitative PCR using an ABI 7900HT 
Taqman sequence detector, following the ‘standard curve’ method. All values were 
subsequently normalized to the averaged ratio of the five corresponding normal samples. For 
DNA copy number determination using the ABI 7900HT sequence detector, we performed 
quantitative PCR analysis using the same mir-17–92 primer set described above, and 
normalized the data against a reference probe corresponding to chromosomal region 6p22 
(forward primer, 3′-GGTCTCTATTTGCACTTGGCTGAT-5′; reverse primer, 3 ′-
TTTTCATTGTTGACCAAGCTAGACA-5′; probe, (6-FAM)-
TAGGGCATACTGCCTGCATATTTCCTGCT-(TAMRA)) or a β-actin probe. The 
reported values represent the ratios of DNA copy number at the mir-17–92 locus to the 
normal reference probe.
Adotptive transfer of Eμ-myc HSCs
Fetal liver-derived HSCs were isolated from Eμ-myc/+ mouse embryos at embryonic day 
(E)13.5–E15.5, and were transduced with MSCV alone or MSCV expressing the mir-17–
19b cluster. To exclude the possibility that the observed acceleration of lymphomagenesis 
was due to insertional mutagenesis, independent experiments were carried out using fetal 
liver cells isolated from eight Eμ-myc/+ embryos. Cells from each isolation were separately 
infected with MSCV mir-17–19b or control MSCV. The MSCV retroviral vector used in our 
studies contains a PGK-puromycin-IRES-GFP (PIG) cassette18. Infection rates, assessed by 
fluorescence-activated cell sorting (FACS), were typically 40% of bulk fetal liver cells. 
HSCs infected with MSCV-mir17–19b-PIG and MSCV-PIG (control) were subsequently 
transplanted into 6–8-week-old, lethally irradiated C57BL/6 recipient mice17. Tumour onset 
was monitored by blood smear analysis, and tumour samples were either collected into 4% 
paraformaldehyde for histopathological studies, or prepared as single-cell suspensions for 
FACS.
We also carried out a screen of 96 miRNAs, to look for miRNA(s) that accelerate Myc-
induced lymphomagenesis. In this experiment, each pre-miRNA (and ~50 bp of flanking 
sequence 5′ and 3′ of the pre-miRNA) was cloned downstream of the cytomegalovirus 
(CMV) promoter in a MSCV vector containing SV40–GFP. Eight individual MSCV 
constructs, each overexpressing a specific miRNA, were pooled at equal concentrations. 
Twelve pools of DNA were used individually to produce virus to infect Eμ-myc/+ fetal liver 
cells for adoptive transfer into at least three recipient animals, as described above. Recipient 
animals were monitored for tumour growth for at least six months. For those that developed 
lymphoma, tumour cells were prepared from the enlarged lymph nodes and then subjected to 
FACS analysis for GFP expression.
Histopathology
Tissue samples were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned into 5-
μm slices, and stained with haemotoxylin and eosin. For Ki67 detection (rabbit anti-Ki67 
antibody, NovoCastra), representative sections were deparaffinized, rehydrated in graded 
alcohols, and processed using the avidin–biotin immunoperoxidase method. Sections were 
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then subjected to antigen retrieval by microwave oven treatment using standard procedures. 
Diaminobenzidine was used as the chromogen and haematoxylin as the nuclear counterstain. 
For B220 immunohistochemistry, a rat anti-mouse CD45R/B220 antibody (clone RA3-6B2, 
BD Biosciences Pharmingen) was used; pretreatment for antigen retrieval was not required. 
Analysis of the rate of apoptotis by TUNEL assay was performed according to a published 
protocol27.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The mir-17–92 cluster shows increased expression in B-cell lymphoma samples and cell 
lines
a, Genomic organization of three polycistronic miRNA clusters is shown. There are five 
paralogous groups located in three homologous clusters (mir-17–92, mir-106a–92 and 
mir-106b–25) with a conserved order: miR-17-5p/miR-106a/miR-106b; miR-18; miR-19a/
miR-19b-1/miR-19b-2; miR-20/miR-93; and miR-92-1/miR-92-2/miR-25 (yellow boxes, pre-
miRNAs; purple boxes, mature miRNAs). b, The level of conservation between human and 
mouse homologues is represented using an mVista plot28. Two alternative isoforms have 
been detected for the human gene, and these are shown schematically1 (dark blue, exons; 
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light blue, introns; orange, the mir-17–92 cluster). c, MicroRNA expression levels in cell 
lines carrying the 13q31-q32 amplicon (including Karpas 1718, OCI-Ly4 and OCI-Ly7) 
were compared to those in leukaemia and lymphoma cell lines lacking this genetic lesion, 
and to normal B-cells isolated from cortical blood (top panel). We included in this analysis 
the OCI-Ly8 cell line, which has previously been identified as a cell line carrying the 
13q31-32 amplicon, but showed no gene dosage increase at the c13orf25 locus in our study. 
Normalized one-channel measurements for 191 human miRNAs were hierarchically 
clustered for all miRNA genes represented on the array. An excerpt of the data is shown, 
and the full cluster analysis is presented in Supplementary Fig. 1. The expression map node 
that correlates with the amplification is shown. The let-7 cluster node is also shown for 
comparison (middle panel). In the cell lines examined, expression levels of the mature 
microRNAs from the mir-17–92 polycistron correlate with the copy number at the mir-17–
92 locus (bottom panel). d, The level of mir-17–92 pri-miRNA was determined by real-time 
quantitative PCR in 46 lymphomas and 47 colorectal carcinomas, and compared to levels 
found in corresponding normal tissues from five individuals. In c and d, error bars indicate 
standard deviation (s.d.).
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Figure 2. Overexpression of the mir-17–19b cluster accelerates c-myc-induced lymphomagenesis 
in mice
a, Schematic representation of the adoptive transfer protocol using Eμ-myc HSCs. b, Mice 
reconstituted with HSCs expressing mir-17–19b in an MSCV retroviral vector (MSCV 
mir-17–19b) or infected with a control MSCV virus were monitored by blood smear analysis 
starting 5 weeks after transplantation. The Kaplan-Meier curves represent the percentage of 
leukaemia-free survival or overall survival. c, External GFP imaging of tumour-bearing 
mice with Eμ-myc/mir-17–19b or Eμ-myc/MSCV shows the overall distribution of tumour 
cells. Eμ-myc/mir-17–19b tumours show a more disseminated phenotype compared with 
control tumours. These animals are representative of their genotype.
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Figure 3. Pathological and immunological analysis of lymphomas produced by cooperation 
between mir-17–19b and c-myc
a, Haemotoxylin and eosin (H&E), Ki67, B220 and TUNEL staining of Eμ-myc/mir-17–19b 
lymph node tumours. The ‘starry sky’ morphology is a hallmark of cell clusters undergoing 
apoptosis (black arrows). Scale bar, 10μm. b, Invasion of visceral organs (liver, spleen, lung 
and kidney) by Eμ-myc/mir-17–19b tumour cells, shown by H&E and B220 staining. 
Invasion was observed both perivascularly and parenchymally in liver. Scale bar, 50μm. c, 
Immunophenotyping of Eμ-myc/mir-17–19b lymphomas. Tumour cells stained positively for 
the B-cell-specific marker B220, but not for the T-cell-specific markers CD4, CD8a and 
Thy1.2. Tumour cells bore cellular characteristics of pre-B cells, staining positively for 
CD19 but not for IgM, a marker of mature B-cells.
He et al. Page 12
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